Business
United States
RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines won US approval for a breakthrough pill that lengthens the lives of patients with advanced pancreatic cancer, a major advance against one of the hardest-to-treat tumor types. The once-daily drug carries a list price of more than $475,000 a year, making it one of the most expen…
Continue Reading on Bloomberg
This article is aggregated from Bloomberg. Click below to read the full story.